The lead Calico neurodegeneration molecule is fosigotifator (ABBV-CLS-7262), an eIF2B activator which targets a key regulator of the highly conserved integrated stress response pathway. Inhibition of this pathway has therapeutic potential in a number of neurodegenerative diseases, such as ALS, Parkinson’s disease and traumatic brain injury. April 26,2023, Calico announces that the first participant had been dosed in a Phase 1b clinical trial (study M23-523; NCT05757141), evaluating fosigotifator as a potential treatment for Vanishing White Matter (VWM) disease.